- Previous Close
51.36 - Open
51.28 - Bid 49.88 x 400
- Ask 50.16 x 200
- Day's Range
49.98 - 51.75 - 52 Week Range
42.75 - 64.47 - Volume
379,091 - Avg. Volume
479,220 - Market Cap (intraday)
2.718B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
116.40 - EPS (TTM)
0.43 - Earnings Date Feb 19, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
69.00
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
www.livanova.comRecent News: LIVN
View More
Performance Overview: LIVN
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIVN
View MoreValuation Measures
Market Cap
2.72B
Enterprise Value
3.05B
Trailing P/E
116.40
Forward P/E
20.92
PEG Ratio (5yr expected)
0.47
Price/Sales (ttm)
2.20
Price/Book (mrq)
2.07
Enterprise Value/Revenue
2.46
Enterprise Value/EBITDA
55.58
Financial Highlights
Profitability and Income Statement
Profit Margin
1.91%
Return on Assets (ttm)
4.34%
Return on Equity (ttm)
1.87%
Revenue (ttm)
1.24B
Net Income Avi to Common (ttm)
23.68M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
346.37M
Total Debt/Equity (mrq)
51.89%
Levered Free Cash Flow (ttm)
124.9M
Research Analysis: LIVN
View MoreCompany Insights: LIVN
LIVN does not have Company Insights
Research Reports: LIVN
View MoreWhat does Argus have to say about LIVN?
LIVANOVA PLC has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about LIVN?
LIVANOVA PLC has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about LIVN?
LIVANOVA PLC has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLivaNova Earnings: Healthcare Utilization and Competitor's Missteps Support Strong Growth
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice Target